瑞格列克联合根治性放疗治疗前列腺癌的专家综述
本文综述雄激素剥夺治疗(ADT)在前列腺癌中的演变,重点讨论口服促性腺激素释放激素(GnRH)拮抗剂瑞格列克与放疗联合应用的特点:起效快、睾酮抑制更完全、停药后恢复快,可更精准界定ADT疗程,但需重新思考ADT机制与目标,并关注患者因副作用自行停药的风险。
要点
- 瑞格列克是首个口服GnRH拮抗剂,获美国食品药品监督管理局(FDA)批准。
- 与黄体生成素释放激素(LHRH)激动剂相比,瑞格列克起效更快、睾酮抑制更完全、停药后恢复更快。
- 瑞格列克联合放疗可更精准界定ADT疗程,但需警惕患者为逃避副作用而自行停药。
核心结论
- 瑞格列克起效快、停药后睾酮恢复快,为联合放疗时更精准界定ADT疗程提供机会,但可能需重新思考ADT的机制与目标。
研究设计与样本
- 本文为专家综述,围绕ADT与放疗联合应用的已知与未知方面,以及瑞格列克在当前局限期前列腺癌治疗范式中的定位进行讨论。
主要发现
- 与LHRH激动剂相比,瑞格列克实现更快更完全的睾酮抑制,并带来更快速的前列腺特异性抗原(PSA)反应。
- 停用瑞格列克后,睾酮恢复比GnRH激动剂或注射型GnRH拮抗剂治疗后更快。
- GnRH拮抗剂与LHRH激动剂相比,提供更快的睾酮抑制并减少ADT相关不良事件的可能性,包括可能减少ADT相关主要心脏事件。
- 口服瑞格列克使患者避免疼痛和注射部位反应,减少为注射而额外就诊,并缩短经历去势睾酮水平副作用的时间。
临床怎么用
- 瑞格列克作为口服制剂,其便利性和耐受性可能增强医生处方ADT的意愿及患者在ADT疗程中的控制感,但伴随患者为逃避ADT副作用而选择停药的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Androgen deprivation therapy (ADT) is an integral component in the management of prostate cancer across multiple disease states. Traditionally, luteinizing hormone-releasing hormone (LHRH) agonists constituted the backbone of ADT. However, gonadotropin-releasing hormone receptor hormone (GnRH) antagonists also are available, which offer faster testosterone suppression and reduced likelihood of ADT-related adverse effects compared with LHRH agonists, including the potential for fewer ADT-associated major cardiac events. Until recently, all forms of LHRH agonists and GnRH antagonist formulations were of parenteral administration. However, recently relugolix gained Food and Drug Administration approval as the first oral GnRH antagonist. Relugolix achieves faster and more complete testosterone suppression compared with an LHRH agonist. This translates to more rapid prostate-specific antigen response compared with LHRH agonists. After discontinuation of relugolix, testosterone recovers faster than after GnRH agonists or injectable GnRH antagonist therapy. Overall, these factors provide opportunities for more precisely defined ADT duration when combined with radiation therapy. The rapid onset and offset of testosterone suppression with relugolix may require physicians to rethink the mechanism and goals of ADT when prescribing. As an oral formulation, relugolix enables patients to avoid pain and injection site reactions, limit extra office visits for injections, and achieve a shorter duration of experiencing the side effects of castrate testosterone levels. This convenience and tolerability may enhance physicians' willingness to prescribe ADT and patients' feeling of control during their ADT course, but the potential advantages are accompanied by the risks of patients choosing to discontinue therapy to escape side effects of ADT. This article focuses on different aspects of what is known and unknown regarding the optimal use of ADT and radiation therapy, and how relugolix, due to its properties, fit into our current treatment paradigms for localized prostate cancer.
引用
- Roy S, Zaorsky NG, Bagshaw HP, et al. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34923058. doi:10.1016/j.ijrobp.2021.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。